Biocon Biologics is a subsidiary of Biocon Ltd, an innovation led global biopharmaceuticals company and India's ﬁrst publicly listed biotech enterprise.
An independent entity, with its own dedicated management, Biocon Biologics consolidates the development, manufacturing and commercialization operations of Biocon’s biosimilars business.
Biocon Biologics is engaged in developing high quality, affordable biosimilars that can expand access to a cutting-edge class of therapies to patients globally. It is the only fully integrated pure play biosimilars organization in the world. The company aspires to transform patient lives through innovative and inclusive healthcare solutions.
“Transforming Healthcare, Transforming Lives”
Most inspiring global leader in Biologics delivering affordable access to innovative and inclusive healthcare solutions, transforming patient lives.
CENTRAL TO OUR MISSION
Patients, People, Partners & Business
- Patient-Centricity & Therapeutic Area Leadership
- Unique Culture with Talent Diversity
- Disruptive & Differentiated Portfolio
- Agile Delivery Capability
- Innovative, Technology-Driven Operating Models
- Excellence in Market Shaping
Wide Global Footprint
The Company is serving patients in U.S., EU, Japan, Latin America, Africa, Middle East and Turkey and the Asia-Paciﬁc regions through its wide biosimilar portfolio and has gained a broad experience in managing the risks entailed in taking advanced therapies from 'bench to bedside' even in the most stringently regulated markets.
As a frontrunner in biosimilars, Biocon Biologics is addressing the needs of patients for affordable biologics across many developed and emerging markets through its recombinant human Insulin, Insulin Glargine, biosimilar Trastuzumab and other biopharmaceuticals.
Global Scale Manufacturing
Biocon Biologics has built large scale, world class manufacturing capacities to support its ambition of making global impact. We have built one of India's largest bio-manufacturing facilities for insulins, monoclonal antibodies and devices. Our insulin manufacturing and R&D facility in Malaysia is the largest integrated insulins facility in Asia.
Highest Standards of Quality & Compliance
Biocon Biologics' state-of-the-art manufacturing facilities are qualiﬁed by various regulatory agencies from developed and emerging markets. With an unwavering commitment to quality assurance and stringent quality controls, the Company is on a mission to go beyond compliance and achieve global standards of excellence.
Biocon has one of the largest global biosimilars portfolios, spanning recombinant human Insulin (rh-Insulin), insulin analogs, monoclonal antibodies and other biologics for diabetes, oncology and immunology.
Patient-Centricity At Its Core
*Number of lives is calculated based on volume supplied
- Serving patient needs with high quality affordable biosimilars
- 2+ billion doses cumulatively of biosimilar insulins provided to patients globally
- 5 biosimilars commercialized so far: Trastuzumab, Pegﬁlgrastim, Bevacizumab, rh-Insulin, Insulin Glargine
- ~2 million* patients served globally through our biosimilars in FY19
- Aiming to impact ~2.6 million* patient lives worldwide in FY20